MX352117B - Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo. - Google Patents

Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.

Info

Publication number
MX352117B
MX352117B MX2014009062A MX2014009062A MX352117B MX 352117 B MX352117 B MX 352117B MX 2014009062 A MX2014009062 A MX 2014009062A MX 2014009062 A MX2014009062 A MX 2014009062A MX 352117 B MX352117 B MX 352117B
Authority
MX
Mexico
Prior art keywords
antibody against
amyloid
peptide
antibody
idiotype
Prior art date
Application number
MX2014009062A
Other languages
English (en)
Inventor
Stubenrauch Kay-Gunnar
Essig Ulrich
Hoesel Wolfgang
Vogel Rudolf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX352117B publication Critical patent/MX352117B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para la determinación inmunológica de un anticuerpo contra el péptido amiloide ß en una muestra que utiliza un inmunoensayo empleando un anticuerpo obtenido de la línea de células DSM ACC2939, caracterizado porque le inmunoensayo comprende un anticuerpo de captación, un anticuerpo trazador y un anticuerpo de detección, en donde el anticuerpo de captación es un anticuerpo antí-idiotipo biotinilado contra un anticuerpo contra el péptido amiloido ß obtenido de la línea de célulcas DSM ACC2939 conjugado a una fase sólida vía estreptavidina, el anticuerpo trazador es un anticuerpo anti-idiotipo contra un anticuerpo contra el péptido amiloide ß obtenido de la línea de células DSM ACC 2939 conjugado a digoxigenina como marca detectable, y el anticuerpo de detección es un anticuerpo contra digoxigenina conjugado a una peroxidasa.
MX2014009062A 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo. MX352117B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08022235 2008-12-22
PCT/EP2009/009160 WO2010072384A1 (en) 2008-12-22 2009-12-18 ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE

Publications (1)

Publication Number Publication Date
MX352117B true MX352117B (es) 2017-11-09

Family

ID=40581970

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011006641A MX2011006641A (es) 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.
MX2014009062A MX352117B (es) 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011006641A MX2011006641A (es) 2008-12-22 2009-12-18 Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.

Country Status (22)

Country Link
US (2) US8614297B2 (es)
EP (1) EP2379601B1 (es)
JP (1) JP5642702B2 (es)
KR (2) KR101777899B1 (es)
CN (2) CN102257010A (es)
AR (1) AR074816A1 (es)
AU (1) AU2009331900A1 (es)
BR (1) BRPI0923544B1 (es)
CA (1) CA2746779C (es)
CY (1) CY1118420T1 (es)
DK (1) DK2379601T3 (es)
ES (1) ES2595981T3 (es)
HR (1) HRP20161398T1 (es)
HU (1) HUE030478T2 (es)
IL (1) IL213343A0 (es)
LT (1) LT2379601T (es)
MX (2) MX2011006641A (es)
PL (1) PL2379601T3 (es)
PT (1) PT2379601T (es)
SI (1) SI2379601T1 (es)
TW (1) TWI424162B (es)
WO (1) WO2010072384A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013177115A2 (en) * 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3176580A1 (en) * 2015-12-01 2017-06-07 Roche Diagnostics GmbH Method for reduction of interferences in immunoassays
JP6918808B2 (ja) * 2016-08-31 2021-08-11 栄研化学株式会社 異なる方式で抗原を固定化した抗原担持不溶性担体粒子を用いる抗体測定法、抗体測定用試薬
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
GB202410666D0 (en) * 2024-07-22 2024-09-04 Micromass Ltd Methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219730A (en) * 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987002778A1 (en) 1985-10-22 1987-05-07 Cooper-Lipotech Solid-phase liposome immunoassay system
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
JPH04507285A (ja) 1988-12-09 1992-12-17 セントコー・インコーポレーテッド 抗イディオトープ免疫検定法
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
NZ255041A (en) 1992-07-13 1996-11-26 Bionebraska Inc Preparation of a recombinant single copy polypeptide or portion thereof modified with a terminal alpha amino carbon reactive group and reactive side chain groups involving biologically added protective groups
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) * 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2003016466A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004092197A2 (en) * 2003-04-07 2004-10-28 The Regents Of The University Of California Amyloid-specific peptides and uses thereof
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
AU2004272112A1 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
CA2543830A1 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
JPWO2005105998A1 (ja) * 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CN101371140B (zh) 2006-03-09 2013-11-13 弗·哈夫曼-拉罗切有限公司 抗药物抗体的测定
US20080127359A1 (en) * 2006-11-06 2008-05-29 Hermann Beck Method for producing anti-idiotypic antibodies
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途

Also Published As

Publication number Publication date
PL2379601T3 (pl) 2017-02-28
HRP20161398T1 (hr) 2016-12-16
KR101777899B1 (ko) 2017-09-13
JP2012513426A (ja) 2012-06-14
TWI424162B (zh) 2014-01-21
US8614297B2 (en) 2013-12-24
LT2379601T (lt) 2016-10-25
JP5642702B2 (ja) 2014-12-17
EP2379601B1 (en) 2016-08-10
MX2011006641A (es) 2011-07-12
AU2009331900A1 (en) 2010-07-01
TW201030335A (en) 2010-08-16
HUE030478T2 (en) 2017-05-29
SI2379601T1 (sl) 2016-11-30
DK2379601T3 (en) 2016-08-29
US20100167313A1 (en) 2010-07-01
US9547010B2 (en) 2017-01-17
BRPI0923544B1 (pt) 2021-11-23
CY1118420T1 (el) 2017-06-28
KR20110086182A (ko) 2011-07-27
CA2746779A1 (en) 2010-07-01
EP2379601A1 (en) 2011-10-26
CN106990251B (zh) 2019-12-27
CN102257010A (zh) 2011-11-23
PT2379601T (pt) 2016-10-04
CA2746779C (en) 2017-01-24
ES2595981T3 (es) 2017-01-04
KR20130088199A (ko) 2013-08-07
CN106990251A (zh) 2017-07-28
US20130323762A1 (en) 2013-12-05
BRPI0923544A2 (pt) 2016-01-26
WO2010072384A1 (en) 2010-07-01
AR074816A1 (es) 2011-02-16
IL213343A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
MX352117B (es) Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.
IN2015DN00091A (es)
MX347197B (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
WO2007133822A8 (en) Gitr antibodies for the treatment of cancer
IN2012DN03338A (es)
WO2008059252A3 (en) Methods and composition fro t cell receptors which recognize 5t4 antigen
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
CL2007003771A1 (es) Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an
MY153893A (en) Antibodies against human il17 and uses thereof
TW200639182A (en) Antibody variants and uses thereof
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2011047087A3 (en) Protein detection via nanoreporters
NZ621170A (en) Anti-human cd52 immunoglobulins
IL221841A0 (en) Antibodies against cancer-associated epitope of variant nfkbib and uses thereof
CR20120127A (es) Anticuerpos monoclonales
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
NZ595863A (en) Antibodies to egfl7 and methods for their use
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
MY166152A (en) Anti-human xcr1 antibodies
EP3483267A3 (en) Integrin alpha 8-beta 1-specific monoclonal antibody